Ipamorelin
Ipamorelin status, growth-hormone secretagogue claims, FDA concerns, stacking uncertainty, and limitations of online protocols.
Open profile →Peptide Library
Profiles distinguish approved medicines, investigational compounds, compounded-drug questions, and research-only materials. No status label is a recommendation.
Read the status first. A molecule discussed in a clinical paper is not automatically equivalent to a vial sold online.
GHK-Cu
How topical cosmetic discussion differs from injectable use, plus FDA safety concerns, evidence limits, and product-quality questions.
Open profile →TB-500
Regulatory status, evidence limitations, identity confusion, quality questions, and safety uncertainty surrounding TB-500.
Open profile →BPC-157
BPC-157 evidence, regulatory status, human-data limitations, safety questions, and the difference between research interest and established treatment.
Open profile →Retatrutide
Current investigational status, trial context, online-product risks, and why retatrutide sold by research vendors is not clinical-trial material.
Open profile →Tesamorelin
What tesamorelin is approved for, what the label does not establish, formulation differences, and why broad weight-loss claims need scrutiny.
Open profile →Tirzepatide
A status-first guide to approved tirzepatide medicines, compounded versions, online products, quality questions, and evidence boundaries.
Open profile →Semaglutide
Approval status, approved-product context, compounded-product cautions, quality questions, and evidence boundaries for semaglutide.
Open profile →